Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Proton Therapy
78%
Lung Cancer
51%
Chemoradiotherapy
48%
Radiation Therapy
30%
Neoplasm
28%
Radiation Therapy
24%
Overall Survival
24%
Intensity Modulated Radiation Therapy
21%
Radiation Pneumonia
16%
Durvalumab
14%
Volume CT
13%
Thorax Tumor
12%
Contouring
12%
Cardiovascular System
12%
Patient Selection
12%
Immunotherapy
12%
Small Cell Lung Cancer
12%
Non-Small Cell Lung Cancer
12%
Lobectomy
12%
Stereotactic Body Radiation Therapy
11%
Breathing
11%
Photon Therapy
11%
Volumetric Modulated Arc Therapy
11%
Conformal Radiotherapy
11%
Image Quality
10%
Positron Emission Tomography
10%
Primary Tumor
10%
Dose Calculation
10%
Lung
9%
Acute Toxicity
9%
Lung Tumor
8%
Treatment Planning
7%
Esophageal Cancer
7%
Cone Beam Computed Tomography
7%
Odds Ratio
7%
Stereotactic Radiotherapy
7%
Radiation Therapy Planning
7%
Fluorodeoxyglucose F 18
7%
Esophageal Cancer
7%
Radiation Oncology
6%
Dose-Volume Histogram
6%
Computer Assisted Tomography
6%
Prognostic Model
6%
Head and Neck Tumor
6%
Continuous Positive Airway Pressure
6%
Tumor Metabolism
6%
Bilevel Positive Airway Pressure
6%
Positron Emission Tomography
6%
Hypoxia
6%
Keyphrases
Non-small Cell Lung Cancer Patients
45%
Chemoradiotherapy
28%
Lung Cancer
24%
Multivariable
18%
Stage I Lung Cancer
18%
Non-small Cell Lung Cancer (NSCLC)
16%
4D Dose Accumulation
16%
Overall Survival
16%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
15%
Radiotherapy
14%
External Validation
13%
Patient Selection
13%
Normal Tissue Complication Probability
12%
Intensity-modulated
12%
Acute Toxicity
12%
Stage III Non-small Cell Lung Cancer
12%
National Cohort Study
12%
Minimally Invasive Lobectomy
12%
Stereotactic Ablative Radiotherapy
12%
Proton Therapy
11%
Normal Tissue Complication Probability Models
11%
4D Dose Reconstruction
10%
Esophageal Toxicity
10%
Stereotactic Body Radiotherapy
9%
Concurrent Chemoradiotherapy
8%
Dutch
7%
Radiation Pneumonitis
7%
Dosimetric Parameters
7%
Model Performance
7%
Deep Learning
7%
Stereotactic Radiotherapy
7%
Organs at Risk
7%
Cancer Audit
6%
2-year Mortality
6%
External Model
6%
Model Update
6%
Prognostic Model
6%
Heart Dose
6%
Interface Test
6%
Immune Checkpoint Inhibitors
6%
Non-responders
6%
CD8+ T Cell Infiltration
6%
Normal Tissue Complications
6%
4DCT
6%
Radiation Dose
6%
Stage I-IIIA
6%
Assessment Method
6%
Intrafraction
6%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
6%
3-month Mortality
6%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
92%
Chemoradiation Therapy
63%
Lung Cancer
44%
Overall Survival
26%
Malignant Neoplasm
25%
Radiation Pneumonia
19%
Primary Tumor
12%
Durvalumab
12%
Neoplasm
9%
Acute Toxicity
9%
Cisplatin
8%
Immunotherapy
7%
Chemotherapy
7%
Comorbidity
7%
Cancer Staging
6%
Brain Metastasis
6%
Thorax Tumor
6%
Pneumonia
6%
Survival Prediction
6%
Tolerability
6%
Hodgkin Disease
6%
Chemotherapy Regimens
6%
Tremelimumab
6%
Heart Left Ventricle Failure
6%
Coronary Artery Calcification
6%
Cardiovascular Risk
6%
Dosimetry
6%
Esophagus Cancer
6%
Lung Toxicity
5%
Cardiovascular Disease
5%
